Global /India /Healthcare /Drug Manufacturers - General /GLAXO
chevron_leftBack

GlaxoSmithKline Pharmaceuticals Ltd.

GLAXO
NSE: GLAXO Delayed
2,846.60INR 1.3%
33.29 USD
As of 24 April 2025, GlaxoSmithKline Pharmaceuticals Ltd. has a market cap of $5.58B USD, ranking #2620 globally and #184 in India. It ranks #227 in the Healthcare sector, and #30 in the Drug Manufacturers - General industry.
Global Rank
2620
Country Rank
184
Sector Rank
227
Industry Rank
30
Key Stats
Market Cap
$5.58BUSD
475.76B INR
Enterprise Value
$5.32BUSD
454.8B INR
Revenue (TTM)
$434.15MUSD
37.05B INR
EBITDA (TTM)
$125.61MUSD
10.74B INR
Net Income (TTM)
$100.69MUSD
8.59B INR
EBITDA Margin
29%
Profit Margin
23%
PE Ratio
55.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Bhushan Akshikar open_in_new
Employees
3,211
Founded
1924
Website
india-pharma.gsk.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.3% 2.1% -4.3% 31% 6.3% 50%
Upcoming Earnings
Earnings Date
Tue, May 13

Markets

Exchange Ticker Price
National Stock Exchange of India
MIC: XNSE
PRIMARY
GLAXO
GlaxoSmithKline Pharmaceuticals Ltd
ISIN: INE159A01016
Shares Out.:
169.406M1 Shares Float: 39.689M2
TV:
SA:
YF:
GF:
BA:
MS:
2.85K INR
Bombay Stock Exchange
MIC: XBOM
500660 (GLAXO)
GlaxoSmithKline Pharmaceuticals Ltd
ISIN: INE159A01016
TV:
SA:
YF:
GF:
BA:
MS:
2.85K INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About GlaxoSmithKline Pharmaceuticals Ltd.

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Similar Companies

Industry: Drug Manufacturers - General (India)
Name
Market Cap diff.
Pfizer Ltd.
PFIZER
$2.28B
194.63B INR
-59%
Sanofi India Ltd.
SANOFI
$1.72B
146.6B INR
-69%
Sanofi Consumer Healthcare India Ltd.
SANOFICONR
$1.33B
113.91B INR
-76%
Marksans Pharma Ltd.
MARKSANS
$1.14B
97.07B INR
-80%
Senores Pharmaceuticals Ltd.
SENORES
$286.64M
24.46B INR
-95%
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
Eli Lilly and Co.
LLY
$744.81B
13K%
Johnson & Johnson
JNJ
$374.44B
7K%
AbbVie Inc.
ABBV
$313.2B
6K%
Novo Nordisk A/S
NOVO-B
$276.68B
1.82T DKK
5K%
Roche Holding AG
RO
$246.36B
204.44B CHF
4K%